Journal
ALZHEIMERS & DEMENTIA
Volume 10, Issue -, Pages S55-S61Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2013.12.012
Keywords
Glucagon-like peptide 1; Alzheimer's disease; Parkinson's disease; Liraglutide; Neuroimaging; FDG-PET; MRI; Neuroinflammation; Amyloid imaging
Categories
Funding
- Medical Research Council, UK
- Alzheimer's Society
- Alzheimer's Drug Discovery foundation
- GE healthcare
- Novo Nordisk
- MRC [G84/6523] Funding Source: UKRI
- Medical Research Council [G84/6523] Funding Source: researchfish
Ask authors/readers for more resources
There is increasing evidence to suggest that glucagon-like peptide 1 (GLP1) analogs are neuroprotective in animal models. In transgenic mice, both insulin and GLP1 analogs reduced inflammation, increased stem cell proliferation, reduced apoptosis, and increased dendritic growth. Furthermore, insulin desensitization was also observed in these animals, and reduced glucose uptake in the brain, as shown on FDG-PET imaging. In this review we discussed the role of PET and MRI in evaluating the effect of GLP1 analogs in disease progression in both Alzheimer's and Parkinson's disease. We have also discussed the potential novel PET markers that will allow us to understand the mechanism by which GLP1 exerts its effects. (C) 2014 The Alzheimer's Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available